Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,555
  • Shares Outstanding, K 40,480
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,960 K
  • 60-Month Beta 2.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +832,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8300 +8.74%
on 07/09/20
2.2400 -11.16%
on 07/23/20
+0.1300 (+6.99%)
since 07/02/20
3-Month
1.5506 +28.34%
on 05/06/20
2.9200 -31.85%
on 05/19/20
+0.4100 (+25.95%)
since 05/05/20
52-Week
0.3510 +466.95%
on 10/02/19
6.0200 -66.94%
on 12/31/19
+1.0600 (+113.98%)
since 08/05/19

Most Recent Stories

More News
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended . All dollar amounts are expressed in Canadian...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

and , /PRNewswire/ Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on , at to discuss a corporate update and financial results for...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight

, /PRNewswire/ --  – Researchers at the Cancer Centerhave found a potential new combination therapy for breast cancer that would integrate the body's immune system with targeted treatment for a protein...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
MKKGY : 26.3300 (+1.54%)
PFE : 38.45 (+0.16%)
ATNX : 11.40 (+1.42%)
BMY : 59.69 (+0.37%)
MRK : 81.64 (-0.04%)
New Drug Developments and Combinations Aiding Badly Neglected Triple-Negative Breast Cancer Patients

, /PRNewswire/ --   – A recent study from the National Comprehensive Cancer Center (NCCN) delivered a shocking indictment of the oncology field as a whole, stating that  of women diagnosed with triple-negative...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
INCY : 97.62 (-2.33%)
RHHBY : 43.4000 (-0.98%)
AZN : 55.95 (-0.23%)
IMMU : 44.38 (+0.54%)
Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

, /PRNewswire/ --   – In a major step forward, engineers from have designed nanoparticles that stimulate the immune system, helping it to attack tumors. This could contribute significantly to other...

RHHBY : 43.4000 (-0.98%)
XYNO : 0.2001 (-19.96%)
CANF : 2.26 (-9.24%)
ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments

, /PRNewswire/ -- The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A  from Cole Market Research has stated that the ongoing advancements in cancer research...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
GNPX : 3.56 (-2.73%)
CRDF : 5.86 (-5.64%)
MRK : 81.64 (-0.04%)
LLY : 154.34 (-0.33%)
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

and , /PRNewswire/ --

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients

, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
PFE : 38.45 (+0.16%)
LLY : 154.34 (-0.33%)
NVTA : 33.36 (+0.76%)
CLVS : 6.47 (+3.44%)
CORT : 14.36 (-8.48%)
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

and , /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)
PFE : 38.45 (+0.16%)
Oncolytics Biotech® Establishes New At-The-Market Facility

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into...

ONCY : 1.9900 (-7.44%)
ONC.TO : 2.64 (-7.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ONCY with:

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

2nd Resistance Point 2.1199
1st Resistance Point 2.0549
Last Price 1.9900
1st Support Level 1.9475
2nd Support Level 1.9051

See More

52-Week High 6.0200
Fibonacci 61.8% 3.8544
Fibonacci 50% 3.1855
Fibonacci 38.2% 2.5166
Last Price 1.9900
52-Week Low 0.3510

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar